PL1660115T3 - Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi - Google Patents

Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi

Info

Publication number
PL1660115T3
PL1660115T3 PL04763431T PL04763431T PL1660115T3 PL 1660115 T3 PL1660115 T3 PL 1660115T3 PL 04763431 T PL04763431 T PL 04763431T PL 04763431 T PL04763431 T PL 04763431T PL 1660115 T3 PL1660115 T3 PL 1660115T3
Authority
PL
Poland
Prior art keywords
csf
useful
plgf
blood stem
stem cell
Prior art date
Application number
PL04763431T
Other languages
English (en)
Inventor
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of PL1660115T3 publication Critical patent/PL1660115T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04763431T 2003-07-29 2004-07-23 Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi PL1660115T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
EP04763431A EP1660115B1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
PL1660115T3 true PL1660115T3 (pl) 2011-11-30

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04763431T PL1660115T3 (pl) 2003-07-29 2004-07-23 Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi

Country Status (21)

Country Link
US (1) US20070036747A1 (pl)
EP (1) EP1660115B1 (pl)
JP (1) JP4855253B2 (pl)
KR (1) KR101192136B1 (pl)
CN (1) CN100534528C (pl)
AT (1) ATE513555T1 (pl)
AU (1) AU2004262909B2 (pl)
BR (1) BRPI0412989A (pl)
CA (1) CA2526244C (pl)
DK (1) DK1660115T3 (pl)
ES (1) ES2369487T3 (pl)
IL (1) IL173369A (pl)
MX (1) MXPA06000017A (pl)
NO (1) NO20060955L (pl)
NZ (1) NZ543612A (pl)
PL (1) PL1660115T3 (pl)
PT (1) PT1660115E (pl)
RU (1) RU2351357C2 (pl)
SI (1) SI1660115T1 (pl)
WO (1) WO2005014023A1 (pl)
ZA (1) ZA200509361B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EA019560B1 (ru) 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
AU2010279398A1 (en) 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
AU2014224042B2 (en) 2013-02-28 2020-04-23 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
EP1147777A1 (en) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
CA2421966A1 (en) * 2000-09-13 2003-03-11 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells

Also Published As

Publication number Publication date
MXPA06000017A (es) 2006-03-21
CN1826134A (zh) 2006-08-30
IL173369A (en) 2010-12-30
KR20060079753A (ko) 2006-07-06
EP1660115A1 (en) 2006-05-31
JP2007500157A (ja) 2007-01-11
NO20060955L (no) 2006-02-27
ATE513555T1 (de) 2011-07-15
CN100534528C (zh) 2009-09-02
AU2004262909B2 (en) 2010-07-01
SI1660115T1 (sl) 2011-10-28
NZ543612A (en) 2008-03-28
ES2369487T3 (es) 2011-12-01
JP4855253B2 (ja) 2012-01-18
DK1660115T3 (da) 2011-10-10
WO2005014023A1 (en) 2005-02-17
KR101192136B1 (ko) 2012-10-16
US20070036747A1 (en) 2007-02-15
PT1660115E (pt) 2011-08-24
CA2526244A1 (en) 2005-02-17
ZA200509361B (en) 2007-03-28
BRPI0412989A (pt) 2006-10-03
AU2004262909A1 (en) 2005-02-17
CA2526244C (en) 2012-03-20
EP1660115B1 (en) 2011-06-22
RU2351357C2 (ru) 2009-04-10
RU2006106228A (ru) 2007-09-10
IL173369A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
AU2002359340A1 (en) Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
MY143795A (en) Tetrahydropyridoindole derivatives
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2006125198A3 (en) Hemodialysis methods and apparatus
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
EP2177531A3 (en) Cell permeable peptide
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
EP1663201A4 (en) USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2003079967A3 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
WO2007008232A3 (en) Locoregional internal radionuclide ablation of abnormal tissues.
MXPA05011788A (es) Compuestos quimicos.
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
WO2004087876A3 (en) Use of red blood cells to facilitate cell activation
PL1663101T3 (pl) Postać stosowana do doustnego podawania substancji czynnych, witamin i/lub substancji odżywczych, zestaw i zastosowanie
WO2004087117A3 (de) Verwendung von cyclischen aketalen/ketalen zur verbesserten penetration von wirkstoffen in zellen und organen
TW200503999A (en) Therapeutic agents
WO2008107785A3 (en) Composition containing autologous mononuclear cells and scaffold and its use in the preparation of a surgical medicament
HUP0203277A2 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
IL169687A0 (en) Methods for the drug prophylaxis of poisoning by cholinesterase inhibitors, and active ingredients and medicaments suitable therefore
CA2463001A1 (en) Solution based methacholine formulations